Nephrocare Health Services Reports Q1 Results and Announces Overseas Entity Restructuring

Nephrocare Health Services Reports Q1 Results and Announces Overseas Entity Restructuring​

Nephrocare Health Services Limited has released its unaudited financial results for the quarter ending June 30, 2026, along with key updates regarding corporate governance and an internal restructuring of its global holding structure. The company also detailed significant asset transfers and provided the status of its subsidiaries’ operations across various geographies.

The Board of Directors reviewed and approved these outcomes during a meeting held on August 11, 2026.

Q1 Financial Performance Highlights​

The company provided both standalone and consolidated financial statements for the quarter ended June 30, 2026. The results were subject to a Limited Review by statutory auditors M/s B S R and Co, Chartered Accountants (FRN - 128510W).

Key figures from the Standalone Financial Results are presented below (in ₹ Million):


The Consolidated Financial Results, which include the performance of the Group and its subsidiaries, show:

Global Restructuring and Governance Updates​

The Board meeting approved several changes relating to corporate governance and international operations:

International Restructuring:
The company is undertaking an internal restructuring of the Group's overseas holding structure. This involves the proposed transfer of the 51% shareholding in Nephrocare Health Services Saudi Arabia Company (NHSSAC) from Nephrocare Health Services International Pte. Ltd. (NHSI), an overseas wholly owned subsidiary, to NephroPlus Kidney Services Company (NPKSC), an overseas step-down wholly owned subsidiary. The proposed transfer involves a cash consideration of Saudi Riyal 2.24 million. The Board noted that the transfer does not alter the ultimate beneficial ownership or control of NHSSAC.

Committee Reconstitutions:
The company approved two key committee reconstitutions, effective from August 17, 2026:

• Audit Committee: The revised composition includes Mr Hemant Sultania (Chairman & Independent Director), Ms Annette Kumlien (Independent Director), and Mr Gaurav Sharma (Nominee Director).
• Stakeholders Relationship Committee: This committee comprises Mr Vishal Vijay Gupta (Chairman & Nominee Director), Mr Vikram Vuppala (Managing Director), and Mr Om Prakash Manchanda (Independent Director).

Geographical Operations Overview​

The consolidated results provided details on the geographical distribution of operations. For the quarter ended June 30, 2026, revenue from operations stood as follows:

Additional Corporate Updates​

The Board also reviewed and approved the utilization of net IPO proceeds (for 18,943,020 equity shares issued during the year) and provided updates on business combinations:

• IPO Utilization: The total planned utilization for capital expenditure, borrowings repayment, and general corporate purposes was INR 3,251.53 million. As of June 30, 2026, amounts utilized included 127.68 million for capital expenditure in India, 1,359.99 million toward pre-payment or scheduled repayment of borrowings, and 587.16 million for general corporate purposes. An unutilized amount totaling 1,176.70 million remains as of June 30, 2026.
• Asset Transfers: The Group entered into seven asset transfer arrangements during the quarter ended June 30, 2026, for an aggregate consideration of INR 709.30 million.

NEPHROPLUS Stock Price Movement​

Today, Nephrocare Health Services Limited saw its stock climb as the company settled at ₹712.30 after gaining 2.77%. The equity traded a total volume of 237,830 shares during the session.